Total Payments
$33,651
2024 Payments
$8,596
Companies
95
Transactions
1,237
Medicare Patients
7,176
Medicare Billing
$5.6M
Payment Breakdown by Category
Food & Beverage$25,246 (75.0%)
Consulting$4,215 (12.5%)
Research$2,302 (6.8%)
Education$1,589 (4.7%)
Other$299.10 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $25,246 | 1,199 | 75.0% |
| Consulting Fee | $4,215 | 2 | 12.5% |
| Unspecified | $2,302 | 4 | 6.8% |
| Education | $1,589 | 29 | 4.7% |
| Long term medical supply or device loan | $299.10 | 3 | 0.9% |
Payments by Type
General
$31,348
1,233 transactions
Research
$2,302
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $2,921 | 17 | $0 (2024) |
| Eli Lilly and Company | $2,302 | 4 | $0 (2023) |
| Cardinal Health 110 LLC | $2,128 | 6 | $0 (2024) |
| Janssen Biotech, Inc. | $1,687 | 66 | $0 (2024) |
| Amgen Inc. | $1,628 | 77 | $0 (2023) |
| PFIZER INC. | $1,473 | 102 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,420 | 64 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,418 | 69 | $0 (2024) |
| Incyte Corporation | $1,310 | 56 | $0 (2024) |
| Celgene Corporation | $1,211 | 76 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,596 | 277 | Cardinal Health 110 LLC ($2,015) |
| 2023 | $6,196 | 249 | Merck Sharp & Dohme LLC ($356.01) |
| 2022 | $6,613 | 211 | Eli Lilly and Company ($2,011) |
| 2021 | $5,529 | 144 | Eisai Inc. ($2,618) |
| 2020 | $1,911 | 98 | Amgen Inc. ($401.22) |
| 2019 | $2,470 | 138 | Amgen Inc. ($355.30) |
| 2018 | $1,502 | 70 | Celgene Corporation ($180.35) |
| 2017 | $833.07 | 50 | E.R. Squibb & Sons, L.L.C. ($225.27) |
All Payment Transactions
1,237 individual payment records from CMS Open Payments — Page 1 of 50
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $5.31 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | Coherus Biosciences Inc. | LOQTORZI (Biological) | Food and Beverage | In-kind items and services | $21.29 | General |
| Category: Oncology | ||||||
| 12/19/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $10.65 | General |
| Category: Hematology | ||||||
| 12/19/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $0.94 | General |
| Category: Hematology | ||||||
| 12/18/2024 | Organon Llc | ONTRUZANT (Drug) | Food and Beverage | In-kind items and services | $21.65 | General |
| Category: TRASTUZUMAB | ||||||
| 12/18/2024 | Organon Llc | ONTRUZANT (Drug) | Food and Beverage | In-kind items and services | $2.02 | General |
| Category: TRASTUZUMAB | ||||||
| 12/17/2024 | Incyte Corporation | PEMAZYRE (Drug), MONJUVI | Food and Beverage | Cash or cash equivalent | $22.69 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 12/16/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TALVEY, TECVAYLI | Food and Beverage | In-kind items and services | $26.85 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $33.78 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $28.61 | General |
| Category: Oncology | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $24.90 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Celgene Corporation | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $16.18 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $19.44 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $27.45 | General |
| Category: NONE | ||||||
| 12/06/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $22.38 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 12/06/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $14.86 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $26.20 | General |
| Category: Oncology | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $24.71 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $6.86 | General |
| Category: Hematology | ||||||
| 12/03/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $6.84 | General |
| Category: Hematology | ||||||
| 12/03/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $2.99 | General |
| Category: Hematology | ||||||
| 12/02/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: Rare Disease | ||||||
| 11/28/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $10.77 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 11/27/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $24.73 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $28.88 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CYCLONE 3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ABEMACICLIB IN COMBINATION WITH ABIRATERONE PLUS PREDNISONE IN MEN WITH HIGH-RISK METASTATIC HORMONE-SENSITIVE PROSTATE CANCER | Eli Lilly and Company | $1,382 | 1 |
| POSTMONARCH: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS FULVESTRANT TO PLACEBO PLUS FULVESTRANT IN PARTICIPANTS WITH HR+, HER2-, ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK4 & 6 INHIBITOR AND ENDOCRINE THERAPY | Eli Lilly and Company | $629.00 | 1 |
| POSTMONARCH: A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS FULVESTRANT TO PLACEBO PLUS FULVESTRANT IN PARTICIPANTS WITH HR+ HER2- ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK4 & 6 INHIBITOR AND ENDOCRINE THERAPY | Eli Lilly and Company | $247.52 | 1 |
| CYCLONE 3: A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF ABEMACICLIB IN COMBINATION WITH ABIRATERONE PLUS PREDNISONE IN MEN WITH HIGH-RISK METASTATIC HORMONE-SENSITIVE PROSTATE CANCER | Eli Lilly and Company | $43.95 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 28 | 1,691 | 89,902 | $1.8M | $724,818 |
| 2022 | 28 | 1,702 | 96,102 | $2.0M | $741,216 |
| 2021 | 29 | 1,856 | 140,902 | $4.2M | $1.7M |
| 2020 | 31 | 1,927 | 94,673 | $6.0M | $2.4M |
Total Patients
7,176
Total Services
421,579
Medicare Billing
$5.6M
Procedure Codes
116
All Medicare Procedures & Services
116 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 83 | 14,100 | $665,050 | $259,249 | 39.0% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 13 | 14,070 | $287,813 | $112,790 | 39.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 268 | 832 | $187,200 | $82,842 | 44.3% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 25 | 53,250 | $118,935 | $46,467 | 39.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 174 | 650 | $107,237 | $43,022 | 40.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 301 | 483 | $89,355 | $33,035 | 37.0% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 13 | 419 | $69,914 | $28,068 | 40.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 31 | 216 | $65,014 | $25,584 | 39.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 88 | 93 | $33,633 | $13,495 | 40.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 82 | 210 | $30,765 | $11,841 | 38.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 57 | 74 | $28,419 | $10,592 | 37.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 27 | 393 | $25,695 | $10,113 | 39.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 49 | 49 | $17,626 | $8,925 | 50.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 132 | 627 | $19,462 | $7,731 | 39.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 54 | 70 | $17,367 | $6,978 | 40.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 41 | 41 | $12,804 | $5,357 | 41.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 14 | 157 | $9,960 | $3,909 | 39.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 11 | 70 | $10,310 | $3,740 | 36.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 38 | 38 | $9,409 | $3,505 | 37.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 25 | 25 | $6,772 | $2,653 | 39.2% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 13 | 64 | $4,913 | $1,974 | 40.2% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 34 | 226 | $3,879 | $1,454 | 37.5% |
| 96368 | Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | Office | 2023 | 17 | 47 | $2,085 | $819.72 | 39.3% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 22 | 2,502 | $632.43 | $234.82 | 37.1% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 23 | 153 | $480.38 | $177.74 | 37.0% |
About Dr. Vu Phan, MD
Dr. Vu Phan, MD is a Hematology & Oncology healthcare provider based in Los Alamitos, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/08/2007. The National Provider Identifier (NPI) number assigned to this provider is 1831247667.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Vu Phan, MD has received a total of $33,651 in payments from pharmaceutical and medical device companies, with $8,596 received in 2024. These payments were reported across 1,237 transactions from 95 companies. The most common payment nature is "Food and Beverage" ($25,246).
As a Medicare-enrolled provider, Phan has provided services to 7,176 Medicare beneficiaries, totaling 421,579 services with total Medicare billing of $5.6M. Data is available for 4 years (2020–2023), covering 116 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Los Alamitos, CA
- Active Since 01/08/2007
- Last Updated 05/19/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1831247667
Products in Payments
- Lenvima (Drug) $2,921
- KEYTRUDA (Biological) $1,386
- IMBRUVICA (Drug) $1,014
- OPDIVO (Biological) $895.28
- JAKAFI (Drug) $731.23
- CALQUENCE (Drug) $672.11
- LIBTAYO (Biological) $596.32
- DARZALEX (Biological) $476.11
- REBLOZYL (Biological) $440.66
- XTANDI (Drug) $439.64
- Nubeqa (Drug) $434.57
- GILOTRIF (Drug) $424.24
- PROVENGE (Drug) $383.17
- VENCLEXTA (Drug) $366.63
- Pomalyst (Drug) $359.98
- ERLEADA (Drug) $347.88
- SARCLISA (Biological) $333.42
- IBRANCE (Drug) $318.49
- XARELTO (Drug) $314.27
- Enhertu (Drug) $292.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Los Alamitos
Dr. Nihal Abdulla, Md, MD
Hematology & Oncology — Payments: $39,752
Hematology & Oncology $39,752
Mario Curti, M.d, M.D
Hematology & Oncology — Payments: $22,717
Hematology & Oncology $22,717
Maria Dungo, M.d, M.D
Hematology & Oncology — Payments: $10,006
Hematology & Oncology $10,006
Dr. Minh Huynh, M.d, M.D
Hematology & Oncology — Payments: $212.64
Hematology & Oncology $212.64